Agilent Technologies registers cedar creek facility with FDA to manufacture diagnostic products
SANTA CLARA Calif. -- Agilent Technologies Inc. (NYSE: A) today announced that its Cedar Creek, Texas, reagent manufacturing facility has been registered with the U.S. Food and Drug Administration as a medical device establishment. This registration is required for the manufacture of diagnostic products, which Agilent intends to develop.
'Many of Agilent's proven research platforms hold potential in diagnostic markets,' said Robert Schueren, Agilent vice president, Genomics. 'We've made a commitment to bring improved diagnostic tools to the medical community. Having an FDA-registered manufacturing facility is yet another step in this endeavor.'
Agilent currently manufactures and packages a wide range of research bioreagents at the 80,000-square-foot Cedar Creek facility, including enzyme-based reagents and high-fidelity oligonucleotides. The company has built separate, dedicated diagnostics space with additional room for expansion as needed.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010. Information about Agilent is available at www.agilent.com.
Related news
-
Medical Baby Monitoring Devices Market Future Growth Explored in Latest Research Report
Fast.MR has published a new report on Global Medical Baby Monitoring Devices market, presenting how Medical Baby Monitoring Devices market is anticipated to unfold during 2020 -2025. The report coverage includes market sizing, and market share data across segments, countries and regions. It also covers market dynamics including growth drivers and restraints which are impacting the growth of market. Key trends shaping the future of market are also presented in report to give reader a better view of market. The...
-
Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available
Avery Biomedical Devices (Commack, NY), the global leader in high reliability diaphragm pacemakers, announced that its new diaphragm pacemaker transmitter, Spirit, has earned FDA approval and is now being offered to patients using its pacing system. This NextGen transmitter features a light-weight compact design with easy-to-use touch controls and offers precision-enhancing digital circuitry. Avery Chief Executive Officer Linda Towler stated, “At Avery, our R&D activities have always been focused on...
-
Avery Biomedical Letter to Medscape Regarding Diaphragm Pacing
Please find below a letter that our attorney sent to the editors of Medscape (parent company WebMD) who have published false information about our product.Medscape Letter Regarding Avery System Avery Biomedical Devices has an outstanding track record spanning over 45 years including an outstanding safety record, long term viability with some patients pacing for more than 35 years, and exceptional patient satisfaction. It is also the only device of its kind with full FDA premarket approval and CE marking privileges...
-
Borealis appoints IMCD as Bormed healthcare portfolio distributor
Distribution agreement to take effect as of 1 October 2021 New agreement applies to Bormed™ portfolio of innovative polyolefin grades for healthcare Complementary Borealis and IMCD product portfolios to enable even more choice in polymers Borealis announces that it has selected IMCD, a global leader in the distribution of specialty chemicals and ingredients, as its new European distributor of its dedicated grade range of Bormed™ polyolefins for healthcare. The distribution agreement covers most...
-
Merck and INBRAIN Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies
Innovation Center project of Merck collaborates to develop smart neuro-modulation for targeted treatment of chronic diseases. Joint development agreement represents a promising step towards a highly selective and efficient next generation of bioelectronic therapies powered by graphene. INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health dedicated to developing the world’s first graphene-based intelligent neuroelectronic system, today announced a collaboration...
Customer comments
No comments were found for Agilent Technologies registers cedar creek facility with FDA to manufacture diagnostic products. Be the first to comment!